Marksans Pharma Ltd., announced Relonchem Ltd., its wholly-owned UK subsidiary, has received Marketing Authorization from the UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) for Gabapentin 50 mg/ml oral solution.

The regulatory approval marks a significant addition to the company’s neurology-focused portfolio in the UK market. Gabapentin is commonly prescribed for the treatment of nerve pain and epilepsy.

Marksans Pharma, headquartered in Mumbai, is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations.

Its facilities in India, the US, and the UK are approved by major global regulatory bodies including the United States Food and Drug Administration (USFDA), UK Medicines and Healthcare Products Regulatory Agency (UKMHRA) and Therapeutic Goods Administration (TGA) Australia.